ArticleDiscover oncology2026
NAT10 promotes colon cancer progression by enhancing predicted N4-acetylcytidine modification of Notch2 mRNA.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColon cancer is a prevalent malignant tumor with high mortality, and RNA modifications play critical roles in its progression. N-acetyltransferase 10 (NAT10)-mediated N4-acetylcytidine (ac4C) modification has emerged as a key epigenetic regulator in gastrointestinal cancers, but its role and mechanism in colon cancer remain unclear. This study investigated whether NAT10 regulates Notch2 via predicted ac4C modification to affect colon cancer progression. MATERIALS AND
methodsNAT10 and Notch2 expression was detected in 15 pairs of colon cancer and adjacent normal tissues. Colon cancer cell lines (HCT116, SW480) and normal colonic epithelial NCM460 cells were used. NAT10 overexpression/knockdown, NAT10 inhibitor Remodelin treatment, rescue experiments in both cell lines, and in vivo xenograft models were performed. CCK-8, Transwell, flow cytometry, TUNEL, acRIP-qPCR, RIP-qPCR, dual-luciferase reporter (WT/MUT), and mRNA stability assays were applied.
resultsNAT10 and Notch2 were significantly upregulated in colon cancer tissues and cells, with a positive correlation trend (r = 0.3571, P = 0.1913). NAT10 knockdown inhibited proliferation, migration, and promoted apoptosis; overexpression exerted opposite effects. Remodelin inhibited NAT10 activity and downregulated Notch2 in a dose-dependent manner. Mechanistically, NAT10 bound to Notch2 mRNA, enhanced its predicted ac4C modification and stability. The predicted 3'UTR ac4C site was critical for NAT10-mediated regulation. Notch2 overexpression reversed NAT10 knockdown effects in both HCT116 and SW480 cells.In vivo subcutaneous xenograft models further confirmed that NAT10 knockdown significantly inhibits colon cancer tumor growth in mice, while Notch2 overexpression effectively rescues this inhibitory effect, supporting the oncogenic role of the NAT10/ac4C/Notch2 axis in vivo.
conclusionNAT10 promotes colon cancer progression in an enzymatic activity‑dependent manner by enhancing predicted ac4C modification of Notch2 mRNA to stabilize its expression. This study reveals a novel NAT10/ac4C/Notch2 regulatory axis and provides potential therapeutic targets for colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.